MCLA-158, the first clinical candidate screened in organoids targeting cancer stem cells of solid tumours

Published in Nature Cancer

An international consortium, co-led by ICREA researcher Dr. Eduard Batlle and the Dutch company Merus N.V., has revealed the preclinical data that led to the discovery of  MCLA-158. This bi-specific antibody targets two proteins, EGFR and LGR5, on the surface of cancer stem cells, slowing the growth of primary tumours in preclinical models of cancer and preventing metastasis. The study has been published in the journal Nature Cancer

The researchers used a biobank of organoids from cancer patients to develop and characterise the effective antibody. The use of organoids in drug discovery has facilitated the identification of therapeutic antibodies and the unwanted side effects of the drugs on organs.

For more information:

Thank you!

We would like to thank all the people and institutions who have made 2022 an exceptional year. Thanks to your contributions, our science is bringing about biomedical breakthroughs that have an increasing impact on people's lives. We would also like to thank all the people and organisations who have joined the Metastasis Challenge.

Every donation, every event, every legacy helps us get one step closer to our goal of stopping metastasis.